AtriCure, Inc (ATRC) insider trading

Every open-market stock purchase and sale by AtriCure, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Sven Wehrwein (Director) and 7 others sold $3.3M in the last 90 days.
  • Last insider buy: Salvatore Privitera (CTO), $111K, 2 years ago.
  • Congress: Gilbert Cisneros sold $1K to $15K, 3 weeks ago.

Last 12 months: insiders bought $0 (0 buys) and sold $4.4M (16 sales). Last close $57.67 on Oct 21, 2026.

Recent ATRC insider trades

DateInsiderTradeValue
Sep 29, 2026Gilbert Cisneros (Representative)Sold$1K–15K
Sep 23, 2026Salvatore Privitera (CTO)Sold$271K
Sep 11, 2026Regina E Groves (Director)Sold$288K
Sep 8, 2026Salvatore Privitera (CTO)Sold$201K
Sep 2, 2026Salvatore Privitera (CTO)Sold$408K
Aug 24, 2026Karl S. Dahlquist (C-suite exec)Sold$458K
Aug 20, 2026Gilbert Cisneros (Representative)Bought$1K–15K
Aug 5, 2026Karen Prange (Director)Sold$138K
Aug 5, 2026Maggie Yuen (Director)Sold$134K
Jul 30, 2026Michael H Carrel (CEO)Sold (not open market)—
Jul 30, 2026Michael H Carrel (CEO)Sold (not open market)—
Jul 29, 2026Justin J Noznesky (Officer)Sold$240K
Jul 28, 2026Sven Wehrwein (Director)Sold$946K
Jul 28, 2026Vinayak Doraiswamy (C-suite exec)Sold$233K
Jul 28, 2026Sven Wehrwein (Director)Bought (not open market)—
Jun 30, 2026Karl S. Dahlquist (C-suite exec)Bought (not open market)$15.1K
Jun 30, 2026Vinayak Doraiswamy (C-suite exec)Bought (not open market)$15.1K
Jun 30, 2026Salvatore Privitera (CTO)Bought (not open market)$15.1K
Jun 30, 2026Michael H Carrel (CEO)Bought (not open market)$15.1K
Jun 30, 2026Douglas J Seith (COO)Bought (not open market)$12.5K
May 20, 2026Karen Prange (Director)Sold$86K
May 18, 2026Shlomo Nachman (Director)Bought (not open market)—
May 18, 2026Deborah H Telman (Director)Bought (not open market)—
May 18, 2026Maggie Yuen (Director)Bought (not open market)—
May 18, 2026Karen Prange (Director)Bought (not open market)—

Who's trading ATRC

Get free alerts when an insider at AtriCure, Inc files a new trade →